In particular, metformin inhibited PCSK9 expression by repressing LXRα, resulting in the downregulation of hepatic lipogenesis-associated genes, which in turn ameliorated olanzapine-induced NAFLD. The gene discussed is NR1H3; the disease is metabolic dysfunction-associated steatotic liver disease.